Taking Mounjaro with PCOS: what the evidence says

Step 1, Understanding why PCOS and tirzepatide are often discussed together

PCOS affects roughly one in ten women of reproductive age in the UK and is one of the most common hormonal conditions seen in primary care. Its hallmarks (irregular cycles, androgen excess, and polycystic-appearing ovaries) are frequently accompanied by insulin resistance, even in women whose blood glucose sits within a normal range. That insulin resistance drives weight gain and makes weight loss harder through conventional means.

Tirzepatide works by activating two gut-hormone receptors: GIP and GLP-1. Both pathways influence appetite, gastric emptying, and blood-sugar regulation. Because the drug targets the same metabolic mechanisms that make weight management so difficult in PCOS, many clinicians and researchers have taken an interest in its potential. Some early data are promising, though large, PCOS-specific randomised trials are still underway. You can read more about the mechanism and evidence base on our dedicated Mounjaro and PCOS page.

For now, the licensed use remains weight management, not PCOS treatment. A prescriber will look at your BMI (the licence threshold is 30 or above, or 27 or above if you have a weight-related condition such as PCOS-related metabolic features), your current medications, your cycle history, and whether you are trying to conceive. That full picture matters more than the diagnosis label alone. The NHS tirzepatide information page sets out the broad clinical context clearly.

Step 2, Contraception, fertility, and the advice you need before starting

This is the section many women with PCOS need most, and it is also where the stakes are highest. PCOS can itself cause irregular or absent periods, so it is tempting to assume pregnancy risk is low. It isn't. Ovulation can occur unpredictably, and unintended pregnancies on tirzepatide have been reported in clinical contexts.

The MHRA, NHS England, and NHS inform Scotland are explicit: use effective contraception while taking Mounjaro and for a wash-out period afterwards before trying to conceive. There is a specific additional requirement for tirzepatide that does not apply to semaglutide in the same way: if you rely on an oral contraceptive pill, add a barrier method for the first four weeks of treatment and for four weeks after every dose increase. Tirzepatide slows gastric emptying, which can reduce how well the pill is absorbed. NHS England's guidance on weight management injections covers this in detail and is worth reading before your consultation.

If you are actively trying to conceive, Mounjaro is not suitable. If you become pregnant during treatment, stop and speak to your GP or midwife the same day. The same applies if you are breastfeeding. These are not provisional recommendations; they are clinical positions based on the absence of safety data in those groups, not just precaution for its own sake.

Step 3, What a prescriber will want to know about your PCOS before approving treatment

At a nume consultation, your prescriber is not just checking BMI. For someone with PCOS, a few specific things will shape the decision.

First, other medications. Metformin is commonly prescribed for PCOS-related insulin resistance, and if you are wondering whether tirzepatide is appropriate alongside treatments used for type 2 diabetes and insulin resistance, our dedicated page covers the key considerations in detail. If you take Metformin, tell your prescriber. The same goes for any hormonal treatments, the contraception point above is not academic if you are on the pill.

Second, thyroid status. A proportion of women with PCOS also have thyroid conditions. Mounjaro carries a warning around a personal or family history of medullary thyroid carcinoma or MEN2; this is a hard contraindication. A history of other thyroid conditions, such as underactive thyroid, does not automatically rule out treatment but is worth disclosing. Our page on Mounjaro and thyroid conditions covers that ground specifically.

Third, liver health. Non-alcoholic fatty liver disease is more common in women with PCOS. If fatty liver has been mentioned in your history, read our guide to Mounjaro and fatty liver disease before your consultation, it is useful background. None of these complexities means treatment is off the table; they mean the consultation does real work.

What is still uncertain, and who to talk to

The honest answer is that PCOS-specific long-term trial data for tirzepatide is limited as of mid-2026. The SURMOUNT-1 trial involved thousands of adults with obesity and documented significant average weight reduction, but it was not powered specifically for PCOS outcomes. Smaller studies and clinical experience suggest improvements in cycle regularity and androgen markers alongside weight loss, but these are not established as licensed outcomes. Things may change as more trial data emerges. For now, the claim a prescriber can make with confidence is weight management, and that is often exactly what women with PCOS need most.

If your PCOS is managed by a gynaecologist or an endocrinologist, it is worth letting them know you are considering or starting tirzepatide, and it is also a good moment to check our guidance on drinking alcohol while taking Mounjaro if that is relevant to your lifestyle. Your GP should also be informed; num​e notifies GPs in line with GPhC guidance as a standard part of the process. You can learn more about our clinical team's approach on the clinical team profile page.

For situations that involve more layers (type 1 diabetes alongside PCOS, for instance) the considerations stack up further. Our page on Mounjaro with type 1 diabetes addresses that combination directly. And if you are ready to discuss your own situation, a free consultation with one of our GPhC-registered prescribers is the right next step.